Levin Capital Strategies, L.P. Summit Therapeutics Inc. Transaction History
Levin Capital Strategies, L.P.
- $1.01 Billion
- Q4 2024
A detailed history of Levin Capital Strategies, L.P. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 36,176 shares of SMMT stock, worth $657,679. This represents 0.06% of its overall portfolio holdings.
Number of Shares
36,176
Previous 36,176
-0.0%
Holding current value
$657,679
Previous $792,000
18.56%
% of portfolio
0.06%
Previous 0.08%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$444 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$212 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$119 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$102 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.66B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...